Trinity Biotech PLC Files 20-F/A Amendment

TL;DR

Trinity Biotech filed an amendment to its 2023 annual report. Check for updates.

AI Summary

Trinity Biotech PLC filed an amendment (20-F/A) on July 12, 2024, for its annual report covering the fiscal year ended December 31, 2023. This filing is an amendment to their previous submission, indicating updates or corrections to the information provided. The company is incorporated in Ireland and operates in the in vitro & in vivo diagnostic substances sector.

Why It Matters

This amendment provides updated or corrected information for Trinity Biotech's 2023 annual report, which is crucial for investors and regulators to have the most accurate financial and operational data.

Risk Assessment

Risk Level: low — This filing is an amendment to an annual report and does not appear to contain new material adverse information, but rather updates or corrections.

Key Numbers

• 2023 — Fiscal Year End (The period covered by the annual report being amended.)
• 20-F/A — Form Type (Indicates this is an amendment to a Form 20-F filing.)

Key Players & Entities

• TRINITY BIOTECH PLC (company) — Filer of the 20-F/A amendment
• 0000888721 (company) — Central Index Key for Trinity Biotech PLC
• 20231231 (date) — Fiscal year end for the reported period
• 20240712 (date) — Filing date of the amendment

FAQ

Key Financial Figures

• $0.0109 — ng 20 A' Ordinary Shares, par value US$0.0109) TRIB NASDAQ Global Select Market

Filing Documents

• zk2431661.htm (20-F/A) — 58KB
• exhibit_12-1.htm (EX-12.1) — 5KB
• exhibit_12-2.htm (EX-12.2) — 5KB
• 0001178913-24-002186.txt ( ) — 295KB
• trib-20231231.xsd (EX-101.SCH) — 5KB
• trib-20231231_def.xml (EX-101.DEF) — 19KB
• trib-20231231_lab.xml (EX-101.LAB) — 26KB
• trib-20231231_pre.xml (EX-101.PRE) — 22KB
• zk2431661_htm.xml (XML) — 10KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No This Annual Report on Form 20-F is incorporated by reference into our Registration Statements on Form S-8 File Nos. 333-182279, 333-195232 and 333-253070 and our Registration Statements on Form F-3 File Nos. 333-264992, 333-267160, 333-279017 and 333-280391. The registrant's auditor is Grant Thornton, Dublin , Ireland (PCAOB ID 1402 ) EXPLANATORY NOTE Trinity Biotech plc (the "Company") is filing this Amendment No. 1 (the "Amendment") to its Annual Report on Form 20-F, filed on April 30, 2024 (the "Original Form 20-F"), solely to correct a typographical error in the description of the exhibit to be incorporated by reference as Exhibit 4.19. Except as described above, no changes have been made to the Original Form 20-F. Furthermore, this Amendment does not change any previously reported financial results, nor does it reflect events occurring after the filing of the Original Form 20-F. Accordingly, this Amendment should be read in conjunction with the Original Form 20-F and the Company's filings with the SEC subsequent to the filing of the Original Form 20-F. Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934 (the "Exchange Act"), this Amendment also includes as exhibits the certifications of the Principal Executive Officer and Principal Financial Officer of the Company pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Item 15 of Form 20-F, paragraphs 3, 4, and 5 have been omitted from such certifications. The Company is not including certifications pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) because no financial statements are filed with this Amendment.

SIGNATURES

SIGNATURES The Registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this Amendment No. 1 to its Annual Report on its behalf. TRINITY BIOTECH PLC By /s/ John Gillard John Gillard Director/ Chief Executive Officer Date: July 12, 2024 By: /s/ Des Fitzgerald Des Fitzgerald Interim Chief Financial Officer Date: July 12, 2024 Item 19 Exhibits Exhibit No. Description of Exhibit 4.19* Second Amended and Restated Credit Agreement and Guaranty, dated as of January 30, 2024 (included as Exhibit 4.21 to our Report on Form 6-K filed on February 1, 2024 and incorporated herein by reference). 12.1 Certification by Chief Executive Officer Pursuant to Section 302 of the Sarbanes- Oxley Act of 2002. 12.2 Certification by Chief Financial Officer Pursuant to Section 302 of the Sarbanes- Oxley Act of 2002. * Certain schedules to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant hereby agrees to furnish a copy of any omitted schedules to the Commission upon request.

View Full Filing

View this 20-F/A filing on SEC EDGAR